A 32-year-old man from rural Odisha presents with fever for 4 days, chills, and myalgia. Thick and thin blood smears show P. falciparum parasitemia of 2.5%. He is conscious, alert, and has no focal neurological signs. His blood glucose is 85 mg/dL, creatinine is 1.8 mg/dL, and haemoglobin is 9.2 g/dL. What is the most appropriate immediate next step in management?

Explanation

## Clinical Assessment This patient has **P. falciparum malaria** with a parasitemia of 2.5% and **no features of severe malaria** (conscious and alert, no focal neurological signs, blood glucose 85 mg/dL, creatinine 1.8 mg/dL — mild-to-moderate impairment but below the severe threshold of >3 mg/dL, Hb 9.2 g/dL — above the severe anaemia threshold of <5 g/dL). ### Key Point: **Intravenous artesunate is the first-line treatment for P. falciparum malaria in India**, per WHO 2023 guidelines and the Indian NVBDCP Malaria Treatment Guidelines 2022. It is preferred over IV quinine due to superior parasite clearance, lower mortality, and a more favourable safety profile. IV artesunate is recommended even in non-severe falciparum malaria when the patient is in a hospital setting, with transition to oral ACT once oral intake is tolerated. ### High-Yield: - **Artesunate dosing:** 2.4 mg/kg IV at 0, 12, and 24 hours, then once daily until oral therapy is feasible. - **Switch to oral ACT** (e.g., artemether-lumefantrine) once the patient can tolerate oral intake. - **Creatinine 1.8 mg/dL** = mild-to-moderate renal impairment; severe AKI in malaria is defined as creatinine >3 mg/dL or urine output <400 mL/24 h — this patient does not meet that threshold. ### Why Not the Other Options? | Option | Reason Incorrect | |---|---| | **A — Exchange transfusion** | Reserved for hyperparasitemia (>10%) with severe malaria and clinical deterioration; not indicated at 2.5% parasitemia | | **C — Oral artemether-lumefantrine as outpatient** | Outpatient oral therapy is inappropriate for a hospitalised patient with P. falciparum; IV artesunate is preferred in the inpatient setting | | **D — IV quinine + ICU** | Quinine is now **second-line** for falciparum malaria per WHO and NVBDCP guidelines; artesunate has demonstrated superior efficacy and lower mortality in multiple RCTs (SEAQUAMAT, AQUAMAT trials). ICU admission is not mandated for uncomplicated falciparum malaria | ### Severe Malaria Criteria (WHO 2023 / Harrison 21e): - Parasitemia >5% (hyperparasitemia) - Cerebral malaria (GCS <11 / unarousable coma) - Acute kidney injury (creatinine >3 mg/dL or oliguria) - Severe anaemia (Hb <5 g/dL) - Pulmonary oedema / ARDS - Metabolic acidosis (bicarbonate <15 mmol/L) - Hypoglycaemia (<40 mg/dL) - Circulatory collapse / shock - Abnormal bleeding / DIC **This patient meets none of these criteria**, confirming uncomplicated falciparum malaria managed with IV artesunate and close monitoring for complications. **Clinical Pearl:** Even in "uncomplicated" falciparum malaria, IV artesunate is preferred over oral therapy in the inpatient setting because of the risk of rapid clinical deterioration and the superior bioavailability of the parenteral formulation. [cite: Harrison's Principles of Internal Medicine 21e, Ch. 219; WHO Guidelines for the Treatment of Malaria, 3rd ed. 2015 (updated 2023); NVBDCP Malaria Treatment Guidelines, India 2022; AQUAMAT trial — Lancet 2010]